Passage BIO, Inc. (PASG) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Passage BIO reported revenue of $0. Net income was -$45.5M, or -$14.35 per diluted share. Operating activities generated -$31.5M of cash, leaving -$31.5M of free cash flow. At fiscal year end, Passage BIO held $62.3M in total assets against $43.5M in total liabilities, including $46.3M of cash and equivalents.
Open the full interactive Passage BIO financials → Quarterly statements, key ratios, valuation history and price charts.
Passage BIO Key Stats
| Share Price | $3.64 |
|---|---|
| Market Cap | $11.7M |
| 52-Week Range | $3.64 – $19.85 |
| Shares Outstanding | 3.2 million (basic, 2026 Q2) |
Passage BIO Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$112.9M | -$185.7M | -$138.4M | -$108.4M | -$70.4M | -$49.3M |
| Pre-Tax Income | -$112.2M | -$185.4M | -$136.1M | -$102.1M | -$64.8M | -$45.5M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$112.2M | -$185.4M | -$136.1M | -$102.1M | -$64.8M | -$45.5M |
| Diluted EPS | -$58.20 | -$69.60 | -$50.00 | -$37.20 | -$21.40 | -$14.35 |
Passage BIO Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.7M | -$13.0M | -$7.6M | -$7.8M |
| Diluted EPS | -$2.44 | -$4.09 | -$2.36 | -$2.44 |
Passage BIO Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $135.0M | $129.0M | $34.6M | $21.7M | $37.6M | $46.3M |
| Current Assets | $317.2M | $325.1M | $197.0M | $118.0M | $78.8M | $47.8M |
| Total Assets | $328.0M | $355.1M | $243.5M | $150.5M | $102.4M | $62.3M |
| Current Liabilities | $21.2M | $29.5M | $18.4M | $16.3M | $19.4M | $23.1M |
| Total Liabilities | $23.3M | $36.4M | $42.2M | $39.3M | $41.2M | $43.5M |
| Shareholders' Equity | $304.7M | $318.7M | $201.4M | $111.3M | $61.3M | $18.8M |
Passage BIO Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$80.5M | -$126.9M | -$118.2M | -$78.3M | -$48.0M | -$31.5M |
| Cash From Investing | -$172.1M | -$45.8M | $25.2M | $65.2M | $54.9M | $40.2M |
| Cash From Financing | $228.8M | $166.7M | -$1.4M | $135,000 | $8.9M | $23,000 |
| Free Cash Flow | — | — | — | — | — | -$31.5M |
Figures from Passage BIO's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Passage BIO financials page for every line item.
Passage BIO Company Profile
| Ticker | PASG |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Philadelphia, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001787297 |
Frequently Asked Questions
What was Passage BIO's revenue in fiscal 2025?
Passage BIO (PASG) reported revenue of $0 for fiscal 2025.
What is Passage BIO's annual revenue history?
Passage BIO's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Passage BIO's net income in fiscal 2025?
Passage BIO reported net income of -$45.5M for fiscal 2025.
What was Passage BIO's earnings per share (EPS) in fiscal 2025?
Passage BIO's diluted EPS was -$14.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Passage BIO generate in fiscal 2025?
Passage BIO generated -$31.5M of free cash flow in fiscal 2025.
What was Passage BIO's revenue last quarter?
In its most recent reported quarter (2026 Q2), Passage BIO reported revenue of $0.
How many shares of Passage BIO are outstanding?
Passage BIO reported a weighted average of 3.2 million basic shares outstanding in 2026 Q2.
What is Passage BIO's market cap?
Based on its latest closing price, Passage BIO (PASG) has a market capitalization of about $11.7M.
When does Passage BIO's fiscal year end?
Passage BIO's fiscal year end, as registered with the SEC, is December 31.
Where is Passage BIO headquartered?
Passage BIO lists its business address in Philadelphia, Pennsylvania in its SEC filings.
Passage BIO Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →